NO20071704L - Prostaglandinderivater for behandling av gastrointestinal forstyrrelse - Google Patents

Prostaglandinderivater for behandling av gastrointestinal forstyrrelse

Info

Publication number
NO20071704L
NO20071704L NO20071704A NO20071704A NO20071704L NO 20071704 L NO20071704 L NO 20071704L NO 20071704 A NO20071704 A NO 20071704A NO 20071704 A NO20071704 A NO 20071704A NO 20071704 L NO20071704 L NO 20071704L
Authority
NO
Norway
Prior art keywords
treatment
gastrointestinal disorder
effective
prostaglandin derivatives
present
Prior art date
Application number
NO20071704A
Other languages
English (en)
Other versions
NO340989B1 (no
Inventor
Ryuji Ueno
Original Assignee
Sucampo Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=35229739&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NO20071704(L) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Sucampo Ag filed Critical Sucampo Ag
Publication of NO20071704L publication Critical patent/NO20071704L/no
Publication of NO340989B1 publication Critical patent/NO340989B1/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D311/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
    • C07D311/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D311/94—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems condensed with rings other than six-membered or with ring systems containing such rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
    • A61K31/558—Eicosanoids, e.g. leukotrienes or prostaglandins having heterocyclic rings containing oxygen as the only ring hetero atom, e.g. thromboxanes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/10—Laxatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nutrition Science (AREA)
  • Hospice & Palliative Care (AREA)
  • Otolaryngology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyrane Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Den foreliggende oppfmnelse vedrører en fremgangsmåte for langtidsbehandling av mageog tarmkanalforstyrrelser hos et menneske, som omfatter å administrere en effektiv mengde av en halogenert prostaglandinforbindelse og/eller dens tautomer til individet. Fremgangsmåten induserer i det vesentlige ikke noe elektrolyttskifte under behandlingstiden. Forbindelsene som anvendes ved den foreliggende oppfinnelse, kan forbedre livskvalitet hos menneskene med mage- og tarmkanalforstyrrelser, er like effektive ved behandling av menn og kvinner, og er også effektive hos et menneske til og med i alderen 65 år og eldre.
NO20071704A 2004-09-02 2007-03-30 Farmasøytisk sammensetning som omfatter en prostaglandinforbindelse for behandling av forstoppelse for å forbedre livskvaliteten hos et menneske, samt anvendelse av en prostaglandinforbindelse ved fremstilling av en farmasøytisk sammensetning for langtidsbehandling av forstoppelse for å forbedre livskvaliteten hos et menneske. NO340989B1 (no)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US60652104P 2004-09-02 2004-09-02
US66631705P 2005-03-30 2005-03-30
US66659305P 2005-03-31 2005-03-31
PCT/JP2005/016464 WO2006025599A1 (en) 2004-09-02 2005-09-01 Prostaglandin derivatives for treating gastrointestinal disorder

Publications (2)

Publication Number Publication Date
NO20071704L true NO20071704L (no) 2007-05-31
NO340989B1 NO340989B1 (no) 2017-07-31

Family

ID=35229739

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20071704A NO340989B1 (no) 2004-09-02 2007-03-30 Farmasøytisk sammensetning som omfatter en prostaglandinforbindelse for behandling av forstoppelse for å forbedre livskvaliteten hos et menneske, samt anvendelse av en prostaglandinforbindelse ved fremstilling av en farmasøytisk sammensetning for langtidsbehandling av forstoppelse for å forbedre livskvaliteten hos et menneske.

Country Status (16)

Country Link
US (2) US8748481B2 (no)
EP (1) EP1791545B1 (no)
JP (4) JP2008511541A (no)
KR (4) KR20170003712A (no)
CN (1) CN102885821A (no)
AR (1) AR050626A1 (no)
AU (1) AU2005278323B2 (no)
BR (1) BRPI0514891A (no)
CA (1) CA2577284A1 (no)
ES (1) ES2603381T3 (no)
IL (1) IL181332A (no)
MX (1) MX2007002602A (no)
NO (1) NO340989B1 (no)
NZ (1) NZ553434A (no)
TW (1) TWI387454B (no)
WO (1) WO2006025599A1 (no)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1562604B1 (en) * 2002-10-23 2012-01-04 Sucampo AG Prostaglandin compounds for the treatment of obesity
US8337891B2 (en) * 2003-07-03 2012-12-25 Sucampo Ag Enteric coated composition comprising prostaglandin analogs as chloride channel opener
CA2637275C (en) 2006-01-24 2014-12-09 R-Tech Ueno, Ltd. Pharmaceutical composition comprising a bi-cyclic compound and method for stabilizing the bi-cyclic compound
US20090030072A1 (en) 2007-07-03 2009-01-29 Sucampo Ag Pharmaceutical combination of opioid and prostaglandin compound
WO2013161973A1 (en) * 2012-04-23 2013-10-31 Sucampo Ag Method for treating irritable bowel syndrome with diarrhea
WO2014119787A1 (ja) 2013-02-04 2014-08-07 大正製薬株式会社 便秘症の予防又は治療薬
WO2014159679A1 (en) 2013-03-12 2014-10-02 The United States Of America, As Represented By The Secretary, Department Of Health & Human Services Methods for using lubiprostone to absorb fluid from the subretinal space

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5166174A (en) 1987-01-28 1992-11-24 K.K. Ueno Seiyaku Oyo Kenkyujo Prostaglandins E and anti-ulcers containing same
US5380709A (en) 1987-01-28 1995-01-10 K.K. Ueno Seiyaku Oyo Kenkyujo Prostaglandins E and anti ulcers containing same
US5225439A (en) 1987-01-28 1993-07-06 K.K. Ueno Seiyaku Oyo Kenkyujo Prostaglandins E and anti ulcers containing same
US5317032A (en) 1987-10-02 1994-05-31 Kabushiki Kaisha Ueno Seiyaku Oyo Kenkyujo Prostaglandin cathartic
DE60039727D1 (de) 1999-10-15 2008-09-11 Sucampo Ag Neue Zusammensetzung enthaltend eine bicyclische Verbindung und ein Glycerid
US6414016B1 (en) * 2000-09-05 2002-07-02 Sucampo, A.G. Anti-constipation composition
TWI302100B (en) * 2001-05-02 2008-10-21 Sucampo Ag Composition for treating drug-induced constipation
AR035242A1 (es) 2001-05-18 2004-05-05 Sucampo Ag Uso de un lipido bioactivo halogenadopara preparar una composicion catartica y compuesto lipido bioactivo halogenado
AU2002330747B2 (en) 2001-08-31 2007-07-19 Sucampo Ag Prostaglandin analogs as chloride channel opener
TWI331920B (en) * 2001-11-14 2010-10-21 Sucampo Ag Unit dosage form for relieving or treating constipation in human patients
US7732487B2 (en) 2001-11-19 2010-06-08 Sucampo Ag Method for treating a disease or condition responsive to opening of C1C-2 channel
AU2003292556B2 (en) * 2002-12-27 2009-09-10 Sucampo Ag Derivatives of prostaglandins for treating abdominal discomfort
US8337891B2 (en) 2003-07-03 2012-12-25 Sucampo Ag Enteric coated composition comprising prostaglandin analogs as chloride channel opener

Also Published As

Publication number Publication date
IL181332A (en) 2015-09-24
JP6408426B2 (ja) 2018-10-17
WO2006025599A1 (en) 2006-03-09
TW200612901A (en) 2006-05-01
KR20140019006A (ko) 2014-02-13
CA2577284A1 (en) 2006-03-09
AU2005278323B2 (en) 2011-03-17
US8748481B2 (en) 2014-06-10
ES2603381T3 (es) 2017-02-27
US20140315994A1 (en) 2014-10-23
EP1791545B1 (en) 2016-08-31
BRPI0514891A (pt) 2008-06-24
TWI387454B (zh) 2013-03-01
AU2005278323A1 (en) 2006-03-09
JP2013049688A (ja) 2013-03-14
NO340989B1 (no) 2017-07-31
JP2018150354A (ja) 2018-09-27
KR20070048221A (ko) 2007-05-08
US20060063830A1 (en) 2006-03-23
JP2015166377A (ja) 2015-09-24
MX2007002602A (es) 2007-04-25
KR20170003712A (ko) 2017-01-09
JP2008511541A (ja) 2008-04-17
NZ553434A (en) 2010-01-29
IL181332A0 (en) 2007-07-04
KR20180033310A (ko) 2018-04-02
EP1791545A1 (en) 2007-06-06
AR050626A1 (es) 2006-11-08
CN102885821A (zh) 2013-01-23

Similar Documents

Publication Publication Date Title
MY144750A (en) Treatment method
NO20070247L (no) Amino-5,5-difenylimidazolonderivater for inhibisjon av beta-sekretase
NO20074999L (no) Metode og preparat for behandling av perifere vaskulaere sykdommer
BRPI0416212A (pt) derivado de piridazinona, composição farmacêutica, uso do derivado, método para o tratamento de um sujeito afligido com uma condição ou doença susceptìvel de melhora pela inibição de fosfodiesterase 4 e produto de combinação
BR0211119A (pt) Composto, método de tratar um paciente que tenha, ou de prevenir um paciente de pegar, uma doença ou condição, uso de um composto, e, método para fabricar um composto
NO20050851L (no) Kaspase-inhibitorer og anvendelser derav
NO20082923L (no) Anvendelse av en CB1 antagonist for behandling av bivirkninger og negative symptomer pa schizofreni
ATE422357T1 (de) Verwendung von allopurinol zur behandlung von bluthochdruck
NO20073337L (no) Fremgangsmater for behandling av andedrettssykdommer ved anvendelse av antagonister av interleukin-1 reseptor type 1
DK1608350T3 (da) Fremgangsm der til forebyggelse, behandling og diagnosticering af lidelser af proteinaggregation
NO20073140L (no) Pyrrolopyraziner og pyralopyraziner som er nyttige som inhibitorer av proteinkinaser
NO20072223L (no) Glykogenfosforylaseinhibitor forbindelser med farmsoytiske preparater av disse
WO2006127007A3 (en) Methods of using adipose tissue-derived cells in the treatment of cardiovascular conditions
BRPI0111591B8 (pt) composto, composição farmacêutica, e, usos de um composto
NZ590839A (en) Treatment of pulmonary arterial hypertension
WO2005076979A3 (en) Diagnosis and therapeutics for cancer
NO20045215L (no) Anvendelse av tio-oxindolderivater for behandling av hudlidelser
NO20064325L (no) Heteroarylaminopyrazolderivativer nyttige for behandling av diabetes
WO2020092618A9 (en) Methods of treating depression, anxiety and sexual dysfunction using the compound pimavanserin
WO2008086452A3 (en) Treatment and prevention of alzheimer's disease
NO20060020L (no) 3-fluorpiperidiner som NMDA/NR2B-antagonister
MY134562A (en) Methods and compositions to treat conditions associated with neovascularization
WO2005060960A3 (en) Use of histamine to treat bone disease
NO20064951L (no) 1,3,4-oksadiazol-2-oner som PPAR delta-modulatorer og deres anvendelse
NO20065079L (no) Materialer og metoder for behandling av koaguleringssykdommer

Legal Events

Date Code Title Description
MM1K Lapsed by not paying the annual fees